Brief: Bionomics To Provide A Corporate Update And Discuss End-Of-Phase 2 Meeting Outcomes On The Development Of BNC210 in PTSD
29/07/2024 23:18
July 29 (Reuters) - Bionomics Ltd BNOXN.MX :
* BIONOMICS TO PROVIDE A CORPORATE UPDATE AND DISCUSS
END-OF-PHASE
2 MEETING OUTCOMES ON THE DEVELOPMENT OF BNC210 IN PTSD ON JULY
31, 2024
Source text for Eikon: ID:nGNX50mgbK
Further company coverage: BNOXN.MX
((reuters.briefs@thomsonreuters.com;))
Recent news on Neuphoria Therapeutics
See all newsBrief: Scancell And Neuphoria Therapeutics Announce Merger Agreement And Financing
NASDAQ RESUMED AT 03:25 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 03:20 PM
Brief: Neuphoria Therapeutics Confirms Discussions On Potential Acquisition By Scancell
Brief: Neuphoria Responds To Lynx1’S Revised Indication Of Interest At A Reduced Price And Premium